Castle Biosciences Q1 2026 slides: revenue beats, guidance raised

Castle Biosciences reported Q1 2026 revenue of $83.7 million, beating consensus by about 8%, and raised full-year revenue guidance to $345 million-$355 million from $340 million-$350 million. Core test volumes were strong, with DecisionDx-Melanoma up 16% year over year to 10,021 reports and TissueCypher up 58% to 11,745, while adjusted gross margin improved to 75.6%. Offseting the top-line strength, adjusted EBITDA turned to a $5.1 million loss from a $13 million profit a year ago.

Analysis

CSTL’s setup is less about a single quarter and more about whether it can convert evidence momentum into payer habit. The key second-order effect is that stronger clinical data can compress reimbursement friction faster than salesforce expansion can, which would create operating leverage with a lag of 2-4 quarters; if that loop works, the market is likely underestimating terminal margin power more than near-term growth. The stock’s main mispricing is probably not revenue — it is the probability that one or two core assays become entrenched enough to finance a broader portfolio without perpetual dilution risk.

The biggest bear case is that the business remains structurally vulnerable to coverage whiplash. When a company is still dependent on evidence-led adoption, any reimbursement setback can hit volume before management has time to reallocate capital, so downside is asymmetric over the next 1-2 quarters if payer tone deteriorates. The decline in lower-priority product volumes is a warning that the portfolio is not equally monetizable, and that commercial focus can improve headline growth while masking weakness beneath the surface.

The market may also be missing that high gross margins do not automatically translate into clean earnings power if the company must keep reinvesting to defend clinical relevance. That creates a “good company, bad P&L” window where the equity can re-rate on guidance raises, but only if investors believe incremental spend is driving durable share gains rather than just delaying profitability. In our view, the debate is less about whether the science is credible and more about whether the go-to-market engine can scale faster than reimbursement and competitive response.

Key Decisions for Investors

• Long CSTL on a 3-6 month horizon into evidence/reimbursement follow-through; target a re-rate toward analyst bands if volume growth remains >15% and gross margin holds above 75%, with downside capped by cash balance but upside dependent on payer adoption.
• Buy CSTL Jan-2027 calls or call spreads to express the view that operating leverage arrives with a lag; structure for a 2-4 quarter thesis window where market starts capitalizing future EBITDA rather than current losses.
• Pair long CSTL / short a slower-growing diagnostics name with weaker evidence momentum, if available in the book, to isolate clinical adoption versus sector beta; this should work best if payer visibility improves and the market rewards differentiated data packages.
• Do not chase after a single strong print; use pullbacks toward prior support to accumulate, since the main risk is a reimbursement headline that can reset expectations abruptly within days.
• If evidence cadence stalls or coverage commentary worsens, cut the long and consider a tactical short via puts, because valuation can compress quickly when growth is still being funded rather than self-financed.